LEGN
Earnings in 9 days · May 12, 2026 · Before open
Signal
Leaning Bearish1!
Price
1
Move+0.30%Quiet session
Volume
1
Volume0.5× avgNormal activity
Technical
1
RSIRSI 81Overbought
PRICE
Prev Close
23.52
Open
23.41
Day Range23.01 – 23.70
23.01
23.70
52W Range16.24 – 45.30
16.24
45.30
25% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-14.6x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.09
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +64% YoY · 60% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 2.0 · FCF negative
Bullish
Key MetricsTTM
Market Cap$4.36B
Revenue TTM$1.03B
Net Income TTM-$297.02M
Free Cash Flow-$230.79M
Gross Margin60.3%
Net Margin-28.8%
Operating Margin-13.2%
Return on Equity-29.2%
Return on Assets-17.1%
Debt / Equity0.41
Current Ratio1.96
EPS TTM$-1.61

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong1 watch3 concern
42/100
Liquidity
1.96Watch
Leverage
0.41Strong
Coverage
-6.3xConcern
ROE
-29.2%Concern
ROIC
-9.5%Concern
Cash
$902MStrong
ANALYST COVERAGE18 analysts
BUY
+162.8%upside to target
L $24.00
Med $62.00consensus
H $75.00
Buy
1689%
Hold
211%
16 Buy (89%)2 Hold (11%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
9/10
Technicals
RSI RangeRSI 81 — Overbought, caution
~
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 1.96 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
PDividend PaymentAug 15, 2026
In 104 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

RallyDeath Cross · 50D trails 200D by 34.7%

+23.1% vs SMA 50 · -19.6% vs SMA 200

Momentum

RSI80.8
Overbought — pullback risk
MACD-0.12
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$45.30+92.0%
EMA 200
$27.44+16.3%
Current
$23.59
EMA 50
$19.72-16.4%
52W Low
$16.24-31.2%
52-Week RangeMid-range
$16.2425th %ile$45.30
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 11 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$1.0B
$1.0B$1.1B
-$0.79
±16%
High11
FY2026(current)
$1.4B
$1.4B$1.6B
+38.9%$0.24
±50%
High11
FY2027
$1.8B
$1.6B$2.0B
+27.2%$0.98+307.2%
±49%
High11
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryLEGN
Last 8Q
+42.0%avg beat
Beat 7 of 8 quartersMissed 1 Estimates rising
+43%
Q1'24
+45%
Q2'24
+91%
Q3'24
+62%
Q1'25
+83%
Q2'25
-55%
Q3'25
+15%
Q4'25
+53%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Cowen & Co.Buy → Hold
Jan 22
DOWNGRADE
ScotiabankSector Perform → Outperform
Apr 17
UPGRADE
Insider Activity
SEC Filings →
0 Buys/1 SellNet Selling
Huang YingCEO
$87K
Mar 25
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
SG Americas Securities, LLC
536K
2
Candriam S.C.A.
470K
3
iA Global Asset Management Inc.
231K
4
Y-Intercept (Hong Kong) Ltd
223K
5
HSBC HOLDINGS PLC
221K
6
Sumitomo Mitsui Trust Holdings, Inc.
167K
7
Raiffeisen Bank International AG
140K
8
Pictet Asset Management Holding SA
99K
News & Activity

LEGN News

20 articles · 4h ago

About

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Country
United States
Elaine QianVice President & Global Head of Human Resources
Guowei FangPresident of Research & Development
Alan BashPresident of CARVYKTI®